Introduction: Patients of rheumatoid arthritis (RA) are prone to osteoporosis and overt fractures. Subclinical vertebral fractures (SVFs) precede overt vertebral fractures. We studied prevalence and risk factors of SVFs among women with RA. Aim: To determine the prevalence of SVFs in women with RA and to study the various risk factors associated with presence of SVFs. Settings and design: Adult patients of RA attending the rheumatology clinic of medicine department at a tertiary teaching hospital in Delhi. One hundred eleven adult women with RA were included. Clinical assessment included anthropometry, body mass index (BMI), duration of RA, disease activity using Clinical Disease Activity Index (CDAI), disease disability using Health Assessment Questionnaire (HAQ), and details of glucocorticoid (GC) use. Thoracic and lumbar vertebrae were graded for presence of VFs using the semi-quantitative method of Genant by two radiologists. Statistical analysis used: Simple descriptive statistics were used to describe prevalence of SVFs. Risk factors for SVFs were tested for significance using the Student's t-test for quantitative variables and chi-square test for qualitative variables. Kappa statistics were calculated for assessment performed by the two radiologists. Two-sided alpha was set at <0.05. Results: Forty nine percent women had SVFs; 40% had 1-3 SVFs, and 9% had >3 SVFs. Women with any SVF were significantly older as compared to women with no SVF. Fifty five percent of women using GCs had any SVF, while 44%, not using GC, had any SVF (P = ns). GC use, duration of RA, CDAI score, HAQ score, BMI, presence of RF, and anti-CCP were not different between women with and without SVFs. Kappa for inter-reader variability among the two radiologists was 0.98.
INTRODUCTION
Rheumatoid arthritis (RA) is an autoimmune disease characterized by symmetric joint inflammation, stiffness and pain, and muscular weakness around the affected joints. The onset of the disease generally occurs between 40 and 60 years of age. [1] It affects 0.5% to 1% of the general population and has an increased prevalence with age. [2, 3] Vertebral fractures (VFs) are the most common type of fragility fracture. They are associated with chronic back pain, loss of height, kyphosis, reduced pulmonary function, abdominal discomfort, disability, and death. [5, 6] The mortality rate, 5 years after a clinical VF, is 20% greater than expected. [7] Mortality rates increase with the number of VFs. The presence of a VF increases the relative risk of future VFs and fragility fractures at other skeletal sites, independent of bone mineral density (BMD). [8] New VFs, even those that are not recognized clinically (subclinical vertebral fractures, SVF), are associated with substantial increase in back pain and functional limitation. [9] There is also substantial evidence from both cross-sectional and longitudinal studies that radiographically detected SVFs are associated with increased morbidity, functional impairment, and reduced quality of life. [13] [14] [15] [16] Currently, no Indian study has addressed this important issue. This cross-sectional observational study was planned to document the prevalence of SVFs in Indian women with RA. Presence of SVFs was documented and compared across sub-groups viz. site, disease duration, disease severity, antibody status, age, body weight, BMI, and glucocorticoid (GC) use. By virtue of low socio-economic status, protein malnutrition, low Vitamin D status, low muscle mass, and low body weight, Indian women are, per se, susceptible to osteoporosis and fragility fractures. We hypothesize that when the pathological insults due to RA are added to this bone-destructive pathway, the prevalence of fragility fractures (especially SVFs) is likely to be higher than that documented in the Western population. Contribution of various risk factors to SVFs was also determined.
Materials and Methods
The study group comprised of women of RA fulfilling the American College of Rheumatology 2010 criteria for the classification of RA who gave informed consent to participate in the study. [17] Women not willing to give consent, those who were pregnant, diabetic, or those taking bone-protective drugs like bisphosphonates, teriparatide, calcitonin, and raloxifene, were not included in the study. Therapeutic intake of Calcium and Vitamin D was allowed. Women having chronic liver, renal, or thyroid disorders were excluded. Patients having overlap of RA with another connective tissue disorder like systemic lupus erythematosis (SLE), progressive systemic sclerosis (PSS) etc. were not included. A sample size of 100 women was decided, as a sample of convenience. Approval for the study was obtained from the Institutional Ethics Committee. Consecutive patients attending the rheumatology clinic at the Lok Nayak Hospital were screened and their informed consent was taken. After they gave consent, patients were recruited and underwent the following assessments. All patients were asked a detailed history of their disease, treatment, diet, lifestyle, and previous fractures. The disease activity of their RA was judged using the Clinical Disease Activity Index (CDAI) assessment tool. [22] Their quality of life was judged according to the Indian Health Assessment Questionnaire (HAQ). [21] Subsequently, all patients underwent laboratory and radiological tests viz. 5 ml of blood for rheumatoid factor and anti-CCP antibody testing and X-rays of the spine. Two X-rays were done using a standardized procedure after proper bowel preparation: a) lateral X-ray of thoracic spine (T4-T12) and b) lateral X-ray of lumbar spine (L1-L5). Thoracic and lumbar vertebrae were visually graded using the semi-quantitative method of Genant. [18] The films were assessed by two expert radiologists (JK and NP), independently. In case of discordance between the assessment of the two radiologists, the senior radiologist (JK) did a blinded re-assessment of the Xrays and this was taken as the final result. Thoracic and lumbar vertebrae were graded on visual inspection of lateral spinal images and generally without direct vertebral measurement as shown in Figures 1, 2 , and 3.
Statistical Analysis
Data recorded in the case forms were collated and analyzed. Results were expressed as means. SVF prevalence was calculated for site, disease duration and compared between two sub-groups, that is, those having no GC exposure and those having had any GC use. Risk factors for SVFs were tested for significance using the Student's t-test for quantitative variables and chi-square test for qualitative variables. Univariate statistical analyses were performed by categorizing patients into three groups based on the result of the semi-quantitative vertebral deformity analysis-no vertebral deformity, any vertebral deformity, or multiple vertebral deformities. Multivariate regression analysis was used to estimate the independent effects of some clinical and laboratory variables for the presence of VFs. Level of interobserver concordance (kappa) was calculated for the assessment performed by the two radiologists. The level of significance was set at P < 0.05. All tests were two-sided. Statistical analysis was performed with the SPSS program (version 21.0, SPSS Inc., Chicago, III).
RESULTS
We recruited 111 women with RA in the study. The baseline demographic variables of these women are shown in Table 1 .
Forty nine percent of the studied women with RA had any SVF; 9% had more than 3 SVFs. The total number of SVFs were 116. The average number of SVFs per woman were 2.15 (range 1-10).
Disease duration and disease activity (as measured by CDAI) are shown in the box-whiskers plots in Figures 4 and 5 . Neither were significantly different among women with and without SVFs. The distribution of autoantibody (RF and ACPA) positivity among women with and without SVFs is shown in Figures 6 and 7 . There was no significant difference in the distribution of women who were seropositive or seronegative for either antibodies, with respect to the presence of SVFs.
ANOVA testing revealed that the variable which was significantly different among women with SVF and those without SVF was age. Women with no SVF were significantly younger than women with >3 SVF. Also, women with 1-3 SVF were significantly younger than women with >3 SVF.
Among the risk factors studied for SVF, 41 women used GC; average cumulative GC dose was 1150 mg. 55% of women using GCs had any SVF, while 44% women not using GC, had any SVF [ Figure 8 ]. The difference of SVF among these two groups of GC use was not statistically significant.
Kappa for inter-reader reliability of the radiographic readings among the two radiologists was 0.98 suggesting a high degree of agreement and thus, accuracy of the Genant scoring.
In summary, our results show that women with any SVF were significantly older as compared to women with no SVF. Duration of RA, CDAI score, HAQ score, BMI, presence of RF, and anti-CCP and GC use were not different between women with and without SVFs.
DISCUSSION
The prevalence of SVF was quite high in our study, at 49%. This is higher than the prevalence of clinical VFs as reported by Magharoui et al. [10] But they had studied clinically overt VFs while we have studied subclinical VFs, which, like all, clinical diseases have a subclinical phase and all do not convert to clinical fractures.
Osteoporosis and fragility fractures are well-known complications of RA. [4] The cause of osteoporosis in RA may be enhanced osteoclastic activity due to inflammatory cytokines and physical inactivity. Studies have demonstrated higher prevalence of VFs in patients with RA than controls, ranging from 22% to 36%. [10, 11] Several studies have also shown that the risk of vertebral or hip fractures is higher in patients with RA than in those with primary (postmenopausal) osteoporosis. [12, 13] This risk has been estimated to be more than two times than in non-RA women. Furthermore, evidence from studies with BMD as the primary endpoint suggests that osteoporosis occurs in patients with RA independently of GC use. [14, 15] However, there is a discrepancy between low BMD and fracture risk, and a number of fractures are observed in RA patients with Tscores, which are not in the osteoporotic range. [16, 17] This discrepancy may be related to alterations of bone quality, which are not captured by BMD measurements such as mineralization, bone matrix, microarchitecture and have been ascribed to inflammation and GC use.
The spine is a key fracture site; however, there is strong evidence of widespread under-diagnosis of VFs. It has been estimated that only 30% of VFs receive clinical attention (which means that the majority of patients with VFs remain undetected). [18] Large-scale prospective studies indicate that only about one in four VFs are clinically recognized. [19] The lack of clinical recognition of fractures (SVFs) is due to both the absence of symptoms and difficulty in determining the cause of symptoms. VFs are not commonly suspected in patients reporting back pain, unless associated with trauma. Because it is often unsuspected clinically, the diagnosis of a VF relies heavily on radiography. Yet, in a study, 50% of radiographic reports failed to report the presence of moderate or severe VFs and many patients (>90%) remained untreated. [20] In our study, as the age of the patients increased, the number of SVF increased. The lack of association of SVF with risk factors like duration of RA, CDAI score, HAQ score, BMI, presence of RF, and anti-CCP antibodies could be due to small sample size. Surprisingly, GC use did not confer a higher risk for SVFs in the study as was reported by earlier studies. [14, 15] This may be because of the low cumulative dose of GC (1150 mg) used by patients in our study.
As many VFs are clinically unappreciated and undiagnosed, but convey increased risk for future fracture and quality of life impairment, knowledge of existing fracture status is necessary for the optimal management. Moreover, the diagnosis and treatment of VFs are attempted only when the patient becomes significantly symptomatic or in asymptomatic patients by using expensive techniques such as BMD assessment by DEXA scanning. The most glaring lacuna is the clinico- radiologic under-appreciation of the importance of SVFs and the need to search for them actively, so that an early, comprehensive bone-protection strategy can be initiated in concordance with appropriate anti-inflammatory therapy in patients with RA.
A simple, cheap, relatively harmless, widely available, and (till date) most standardized radiographic tool like X-ray was used in our study. Recently, it has been shown that the interreader reproducibility of the semi-quantitative approach, in the hands of experienced and trained readers, has a high degree of reliability for the identification of vertebral deformities. [23] Our study has some lacunae. The sample size was small and we did not have enough patients so that some associations with conventional risk factors for osteoporosis and VFs may have been missed. We did not recruit healthy controls to check and compare the prevalence of SVFs in the normal population, due to denial of permission from the ethics committee.
We did not check serum levels of Vitamin D, calcium, and DEXA bone densitometry to objectively assess bone density. Further, since this was a point prevalence study, we do not have longitudinal data of women who had subclinical VFs.
The key message from our study is that almost half of the women with RA have more than two subclinical VFs, on an average. They portend a higher risk of overt fractures in the future. These covert fractures could not be accounted for by traditional risk factors and hence, all physicians caring for these women should be aware. Bone-protection and bone-strengthening measures must be reinforced at each visit.
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